Peter Dogterom

1.1k citations

41 papers · 896 indexed · h-index 18

Biological Psychiatry top 10%
Pharmacology top 5%
- Pharmacogenetics and Drug Metabolism 7
- Drug-Induced Hepatotoxicity and Protection 6
Internal Medicine top 10%
Pharmaceutical Science top 10%
Pharmacology top 10%
- Pharmacogenetics and Drug Metabolism 7
- Drug-Induced Hepatotoxicity and Protection 6
Psychiatry and Mental health
- Epilepsy research and treatment 6
- Schizophrenia research and treatment 4
Analytical Chemistry
- Analytical Methods in Pharmaceuticals 5
Pediatrics, Perinatology and Child Health
- Pharmaceutical studies and practices 5
Biochemistry
- Eicosanoids and Hypertension Pharmacology 4
Oncology
- Drug Transport and Resistance Mechanisms 4

Co-authors: Gerard J. Mulder J. Fred Nagelkerke Filippos Kesisoglou Amitava Mitra Gerhard Zbinden Rik de Greef Gerd Reznik Jan Jaap Rothuizen
Cited by: Biological Psychiatry Pharmacology Internal Medicine
Journals: Clinical and Translational Science (3 papers)Biochemical Pharmacology (3 papers)Chemico-Biological Interactions (3 papers)
Partner nations: Netherlands United States Switzerland

In The Last Decade

Peter Dogterom

40 papers receiving 858 citations

Peers

Countries citing papers authored by Peter Dogterom

Since Specialization

Citations

This map shows the geographic impact of Peter Dogterom's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Dogterom with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Dogterom more than expected).

Fields of papers citing papers by Peter Dogterom

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Dogterom. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Dogterom. The network helps show where Peter Dogterom may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Peter Dogterom, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Peter Dogterom Line = papers co-authored together Peter Dogterom links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	P-109. A Phase I First-in-Human Study to Evaluate the Safety and Pharmacokinetic (PK) Properties of the Intravenously (IV) Administered OMN6, A Novel Antimicrobial Peptide Targeting Acinetobacter baumannii (AB), in Adults including Older Healthy Volunteers (HVs) Subjects Open Forum Infectious Diseases ·T.V. Savitskaya,黄弢,M. H. Ballance,Yaoyao Men,Valentin Jalba,Peter Dogterom,伊東学,Andrew F. Shorr,Бердюгин И. А.,Lucas Plotegher	2025	1
2	Pilot Clinical Study Showing Abnormal Copper Metabolism in Healthy Wilson Disease Heterozygote Subjects Clinical and Translational Science ·Bernard Bénichou,Kusal Lana,Peter Dogterom,Thomas Damgaard Sandahl,Lorenzo D’Antiga,Michael L. Schilsky	2025	0
3	Relative bioavailability and food effect of the galectin-3 inhibitor selvigaltin (GB1211) administered as a tablet in healthy participants (GALBA-1) Cancer Chemotherapy and Pharmacology ·Vassilios Aslanis,伊東学,Robert J. Slack,C. P.,Lise Gravelle,A. Azimipour,Frank José Gutierrez Sivira,A DALGLEISH,Ian Holyer,B. Sovetbekov,Peter Dogterom,Susan Tantawi,Fredrik R. Zetterberg,زهرا مهدوی لنجی,Hans Schambye,Bertil Lindmark	2024	1
4	Safety, Tolerability, Pharmacokinetics and Initial Pharmacodynamics of a Subcommissural Organ-Spondin-Derived Peptide: A Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose First-in-Human Study Neurology and Therapy ·Valérie Bourdès,Peter Dogterom,André Alemán,Pierre Parmantier,Damien Colas,Sighild Lemarchant,G.S. Sarkisyan,Thomas T. Chou,伊東学,Yann Godfrin	2022	5
5	Comparison of the Pharmacokinetic Profiles of Trientine Tetrahydrochloride and Trientine Dihydrochloride in Healthy Subjects European Journal of Drug Metabolism and Pharmacokinetics ·Karl Heinz Weiss,Catherine Thompson,Peter Dogterom,Juliane Vidal,RichardL. Humphrey,Filipa Moreira‐Silva,Naseem Amin,C. Omar F. Kamlin	2021	10
6	Asenapine pharmacokinetics and tolerability in a pediatric population Drug Design Development and Therapy ·Peter Dogterom,Robert Riesenberg,Rik de Greef,E.G. Lowell,Martin Johnson,Hanna Molla,André M. M. Miltenburg,Robert L. Findling,Abhijeet Jakate,Timothy J. Carrothers,Matthew D. Troyer	2018	6
7	Application of Absorption Modeling to Predict Bioequivalence Outcome of Two Batches of Etoricoxib Tablets AAPS PharmSciTech ·Amitava Mitra,Filippos Kesisoglou,Peter Dogterom	2014	53
8	Maximum Tolerated Dose Evaluation of the AMPA Modulator Org 26576 in Healthy Volunteers and Depressed Patients Drugs in R&D ·Bencai Du,Roberta Bursi,Peter Dogterom,Larry Ereshefsky,Lev Gertsik,Tim Mant,J. Schipper	2012	17
9	Asenapine Safety, Tolerability, and Pharmacokinetics After Single and Multiple Doses in Healthy Volunteers Clinical Pharmacology in Drug Development ·Peter Dogterom,C. J. Timmer,Rik de Greef,Edwin Spaans,K. Varaprasad,André van Vliet,Pierre Peeters	2012	7
10	Asenapine Pharmacokinetics in Hepatic and Renal Impairment Clinical Pharmacokinetics ·Pierre Peeters,Howard N. Bockbrader,Edwin Spaans,Peter Dogterom,Kenneth C. Lasseter,Thomas Marbury,MA Mei-hub,Rik de Greef	2011	21
11	Valproate Reduces the Glucuronidation of Asenapine Without Affecting Asenapine Plasma Concentrations The Journal of Clinical Pharmacology ·Julia M. Malova,Rik de Greef,Peter Dogterom,Pierre Peeters	2011	14
12	Effects of Rifampin on the Disposition of Gepirone ER and Its Metabolites Y. W. Francis Lam,Larry Ereshefsky,Andreas Port,C. J. Timmer,Peter Dogterom	2009	3
13	Absence of Pharmacokinetic Interactions of the Combined Contraceptive Vaginal Ring NuvaRing?? with Oral Amoxicillin or Doxycycline in Two Randomised Trials Clinical Pharmacokinetics ·Peter Dogterom,Michiel W. van den Heuvel,T. Thomsen	2005	19
14	Troglitazone has no effect on red cell mass or other erythropoietic parameters European Journal of Clinical Pharmacology ·T. Arndt,Lisa Squassante,J. Wemer,Sjoerd P. van Marle,Peter Dogterom,J. H. G. Jonkman	1999	29
15	EFFECT OF FELBAMATE ON THE PHARMACOKINETICS OF CLONAZEPAM American Journal of Therapeutics ·Robert D. Colucci,Paul Glue,Christopher Banfield,Pascale Reidenberg,贺金才,Elaine Radwanski,C.A. Korduba,Chih‐Hsiang Lin,Peter Dogterom,Tjark Ebels,Gert‐Jan Hendriks,J. Toulouse,M B Affrime	1996	3
16	Differential effects of extracellular calcium on lipid peroxidation dependent (ethacrynic acid and allyl alcohol) and lipid peroxidation independent (disulfiram)-induced cytotoxicity in normal and vitamin e-deficient rat hepatocytes Chemico-Biological Interactions ·Peter Dogterom,Gerard J. Mulder	1993	7
17	Cardiotoxicity of Vasodilators and Positive Inotropic/Vasodilating Drugs in Dogs: An Overview Critical Reviews in Toxicology ·Peter Dogterom,Gerhard Zbinden,Gerd Reznik	1992	52
18	Lipid peroxidation and protein thiol depletion are not involved in the cytotoxicity of N-hydroxy-2-acetylaminofluorene in isolated rat hepatocytes Biochemical Pharmacology ·E. Dinant Kroese,Gerard Bannenberg,Peter Dogterom,A.B.J. Noach,J. Fred Nagelkerke,John H.N. Meerman	1990	9
19	Lipid peroxidation-dependent and -independent protein thiol modifications in isolated rat hepatocytes: Differential effects of vitamin E and disulfiram Chemico-Biological Interactions ·Peter Dogterom,Gerard J. Mulder,J. Fred Nagelkerke	1989	33
20	Inhibition of lipid peroxidation by disulfiram and diethyldithiocarbamate does not prevent hepatotoxin-induced cell death in isolated rat hepatocytes. A study with allyl alcohol, tert-butyl hydroperoxide, diethyl maleate, bromoisovalerylurea and carbon tetrachloride Chemico-Biological Interactions ·Peter Dogterom,J. Fred Nagelkerke,J. Van Steveninck,Gerard J. Mulder	1988	39

About Peter Dogterom

Peter Dogterom is a scholar working on Pharmacology, Applied Microbiology and Biotechnology, Biochemistry, Psychiatry and Mental health and Analytical Chemistry, having authored 41 papers that have together received 896 indexed citations. Recurring topics across this work include Pharmacogenetics and Drug Metabolism (7 papers), Drug-Induced Hepatotoxicity and Protection (6 papers), Epilepsy research and treatment (6 papers), Analytical Methods in Pharmaceuticals (5 papers), Pharmaceutical studies and practices (5 papers), Eicosanoids and Hypertension Pharmacology (4 papers), Schizophrenia research and treatment (4 papers) and Drug Transport and Resistance Mechanisms (4 papers). The work is most often cited by research in Biological Psychiatry (52 citations), Pharmacology (153 citations), Internal Medicine (47 citations), Pharmaceutical Science (53 citations) and Pharmacology (145 citations). Peter Dogterom has collaborated with scholars based in Netherlands, United States and Switzerland. Frequent co-authors include Gerard J. Mulder, J. Fred Nagelkerke, Filippos Kesisoglou, Amitava Mitra, Gerhard Zbinden, Rik de Greef, Gerd Reznik, Jan Jaap Rothuizen, Martine Jandrot‐Perrus and J. Van Steveninck. Their work appears in journals such as Clinical and Translational Science, Biochemical Pharmacology, Chemico-Biological Interactions, Biomedical Chromatography and European Journal of Clinical Pharmacology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact